Covalent drugs have been used to treat diseases for more than a century, but tools that
facilitate the rational design of covalent drugs have emerged more recently. The purposeful …

Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate numerous cellular
processes. Deregulation of FGFR signalling is observed in a subset of many cancers …

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient,–. Previous …

ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including
BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic …

Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug
discovery. Covalency affords a unique set of advantages as well as challenges relative to …

Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …

FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid
target in FGFR-deregulated tumors. Here, we examine the preclinical profile of futibatinib …

FGFRs are receptor tyrosine kinases with a role in several biological processes, such as the
regulation of development and tissue repair. However, alterations in FGFRs 1–4, such as …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases
expressed on the cell membrane that play crucial roles in both developmental and adult …